According to the paper's first author, Si Ming Man, Ph.D., a postdoctoral fellow in St. Jude Immunology, the findings could lead to new protective treatments
against tularemia, including drugs that can enhance the ability of IRF1, GBP or AIM2 to cure infections more quickly and effectively.